| Identification | Back Directory | [Name]
Lusutrombopag | [CAS]
1110766-97-6 | [Synonyms]
S888711
S 888711
S888711;S 888711
Lusutrombopag S-888711
(E)-3-[2,6-dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]thiazol-2-ylcarbamoyl]phenyl]-2-methylacrylic acid
2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)- | [Molecular Formula]
C29H32Cl2N2O5S | [MOL File]
1110766-97-6.mol | [Molecular Weight]
591.55 |
| Chemical Properties | Back Directory | [density ]
1.299±0.06 g/cm3(Predicted) | [solubility ]
DMSO: 30 mg/ml | [form ]
A crystalline solid | [pka]
4.33±0.21(Predicted) | [color ]
White to off-white | [InChIKey]
NOZIJMHMKORZBA-KJCUYJGMSA-N | [SMILES]
C(O)(=O)/C(/C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OCCCCCC)C)=C3OC)=CS2)=O)C=C1Cl |
| Hazard Information | Back Directory | [Uses]
Lusutrombopag is a newly discovered thrombopoietin receptor agonist used in the treatment of patients with chronic ITP. | [Definition]
ChEBI: Lusutrombopag is a member of cinnamic acids. |
|
|